Pancreatic neuroendocrine tumors

Presentation, management, and outcomes

Nicholas N. Nissen, Amanda S. Kim, Run Yu, Edward M. Wolin, Marc L. Friedman, Simon K. Lo, Ashley M. Wachsman, Steven D. Colquhoun

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Pancreatic neuroendocrine tumors (pNETs) are an uncommon pancreatic neoplasm. We reviewed the presentation, management, and outcome of patients with pNETs treated at a single center by a multidisciplinary approach between 2004 and 2008. Over this time period, 154 patients with carcinoid and neuroendocrine tumors were treated, which included 46 patients (30% of total) with pNETs. The most common presentations included abdominal pain (20 of 46 [43%]), systemic symptoms such as hypoglycemia (15 of 46 [33%]), and incidental mass (7 of 46 [15%]). Fourteen patients had functional tumors. At the time of diagnosis, 22 patients (48%) presented without metastases and 24 (52%) had metastatic disease. Median follow up for the entire group was 42 months. All patients with nonmetastatic pNET underwent pancreatic resection with 95 per cent postoperative survival. Overall survival in this group at 3 years was 86 per cent and disease-free survival was 81 per cent. In patients presenting with metastatic pNET, multiple treatment modalities were used, including liver resection or ablation (n = 15), hepatic chemoembolization (n = 17), pancreatic resection (n = 12), and systemic treatments (n = 7). Three-year survival was 70 per cent. Pancreatic resection results in greater than 80 per cent 3-year survival in nonmetastatic pNET. In patients presenting with metastatic pNET, excellent survival rates are also achievable using a multidisciplinary multimodal approach.

Original languageEnglish (US)
Pages (from-to)1025-1029
Number of pages5
JournalAmerican Surgeon
Volume75
Issue number10
StatePublished - Oct 2009
Externally publishedYes

Fingerprint

Neuroendocrine Tumors
Survival
Liver
Carcinoid Tumor
Pancreatic Neoplasms
Hypoglycemia
Abdominal Pain
Disease-Free Survival
Survival Rate
Neoplasm Metastasis
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Nissen, N. N., Kim, A. S., Yu, R., Wolin, E. M., Friedman, M. L., Lo, S. K., ... Colquhoun, S. D. (2009). Pancreatic neuroendocrine tumors: Presentation, management, and outcomes. American Surgeon, 75(10), 1025-1029.

Pancreatic neuroendocrine tumors : Presentation, management, and outcomes. / Nissen, Nicholas N.; Kim, Amanda S.; Yu, Run; Wolin, Edward M.; Friedman, Marc L.; Lo, Simon K.; Wachsman, Ashley M.; Colquhoun, Steven D.

In: American Surgeon, Vol. 75, No. 10, 10.2009, p. 1025-1029.

Research output: Contribution to journalArticle

Nissen, NN, Kim, AS, Yu, R, Wolin, EM, Friedman, ML, Lo, SK, Wachsman, AM & Colquhoun, SD 2009, 'Pancreatic neuroendocrine tumors: Presentation, management, and outcomes', American Surgeon, vol. 75, no. 10, pp. 1025-1029.
Nissen NN, Kim AS, Yu R, Wolin EM, Friedman ML, Lo SK et al. Pancreatic neuroendocrine tumors: Presentation, management, and outcomes. American Surgeon. 2009 Oct;75(10):1025-1029.
Nissen, Nicholas N. ; Kim, Amanda S. ; Yu, Run ; Wolin, Edward M. ; Friedman, Marc L. ; Lo, Simon K. ; Wachsman, Ashley M. ; Colquhoun, Steven D. / Pancreatic neuroendocrine tumors : Presentation, management, and outcomes. In: American Surgeon. 2009 ; Vol. 75, No. 10. pp. 1025-1029.
@article{ec8b60099c7d4c71b197fc9cbfc04649,
title = "Pancreatic neuroendocrine tumors: Presentation, management, and outcomes",
abstract = "Pancreatic neuroendocrine tumors (pNETs) are an uncommon pancreatic neoplasm. We reviewed the presentation, management, and outcome of patients with pNETs treated at a single center by a multidisciplinary approach between 2004 and 2008. Over this time period, 154 patients with carcinoid and neuroendocrine tumors were treated, which included 46 patients (30{\%} of total) with pNETs. The most common presentations included abdominal pain (20 of 46 [43{\%}]), systemic symptoms such as hypoglycemia (15 of 46 [33{\%}]), and incidental mass (7 of 46 [15{\%}]). Fourteen patients had functional tumors. At the time of diagnosis, 22 patients (48{\%}) presented without metastases and 24 (52{\%}) had metastatic disease. Median follow up for the entire group was 42 months. All patients with nonmetastatic pNET underwent pancreatic resection with 95 per cent postoperative survival. Overall survival in this group at 3 years was 86 per cent and disease-free survival was 81 per cent. In patients presenting with metastatic pNET, multiple treatment modalities were used, including liver resection or ablation (n = 15), hepatic chemoembolization (n = 17), pancreatic resection (n = 12), and systemic treatments (n = 7). Three-year survival was 70 per cent. Pancreatic resection results in greater than 80 per cent 3-year survival in nonmetastatic pNET. In patients presenting with metastatic pNET, excellent survival rates are also achievable using a multidisciplinary multimodal approach.",
author = "Nissen, {Nicholas N.} and Kim, {Amanda S.} and Run Yu and Wolin, {Edward M.} and Friedman, {Marc L.} and Lo, {Simon K.} and Wachsman, {Ashley M.} and Colquhoun, {Steven D.}",
year = "2009",
month = "10",
language = "English (US)",
volume = "75",
pages = "1025--1029",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "10",

}

TY - JOUR

T1 - Pancreatic neuroendocrine tumors

T2 - Presentation, management, and outcomes

AU - Nissen, Nicholas N.

AU - Kim, Amanda S.

AU - Yu, Run

AU - Wolin, Edward M.

AU - Friedman, Marc L.

AU - Lo, Simon K.

AU - Wachsman, Ashley M.

AU - Colquhoun, Steven D.

PY - 2009/10

Y1 - 2009/10

N2 - Pancreatic neuroendocrine tumors (pNETs) are an uncommon pancreatic neoplasm. We reviewed the presentation, management, and outcome of patients with pNETs treated at a single center by a multidisciplinary approach between 2004 and 2008. Over this time period, 154 patients with carcinoid and neuroendocrine tumors were treated, which included 46 patients (30% of total) with pNETs. The most common presentations included abdominal pain (20 of 46 [43%]), systemic symptoms such as hypoglycemia (15 of 46 [33%]), and incidental mass (7 of 46 [15%]). Fourteen patients had functional tumors. At the time of diagnosis, 22 patients (48%) presented without metastases and 24 (52%) had metastatic disease. Median follow up for the entire group was 42 months. All patients with nonmetastatic pNET underwent pancreatic resection with 95 per cent postoperative survival. Overall survival in this group at 3 years was 86 per cent and disease-free survival was 81 per cent. In patients presenting with metastatic pNET, multiple treatment modalities were used, including liver resection or ablation (n = 15), hepatic chemoembolization (n = 17), pancreatic resection (n = 12), and systemic treatments (n = 7). Three-year survival was 70 per cent. Pancreatic resection results in greater than 80 per cent 3-year survival in nonmetastatic pNET. In patients presenting with metastatic pNET, excellent survival rates are also achievable using a multidisciplinary multimodal approach.

AB - Pancreatic neuroendocrine tumors (pNETs) are an uncommon pancreatic neoplasm. We reviewed the presentation, management, and outcome of patients with pNETs treated at a single center by a multidisciplinary approach between 2004 and 2008. Over this time period, 154 patients with carcinoid and neuroendocrine tumors were treated, which included 46 patients (30% of total) with pNETs. The most common presentations included abdominal pain (20 of 46 [43%]), systemic symptoms such as hypoglycemia (15 of 46 [33%]), and incidental mass (7 of 46 [15%]). Fourteen patients had functional tumors. At the time of diagnosis, 22 patients (48%) presented without metastases and 24 (52%) had metastatic disease. Median follow up for the entire group was 42 months. All patients with nonmetastatic pNET underwent pancreatic resection with 95 per cent postoperative survival. Overall survival in this group at 3 years was 86 per cent and disease-free survival was 81 per cent. In patients presenting with metastatic pNET, multiple treatment modalities were used, including liver resection or ablation (n = 15), hepatic chemoembolization (n = 17), pancreatic resection (n = 12), and systemic treatments (n = 7). Three-year survival was 70 per cent. Pancreatic resection results in greater than 80 per cent 3-year survival in nonmetastatic pNET. In patients presenting with metastatic pNET, excellent survival rates are also achievable using a multidisciplinary multimodal approach.

UR - http://www.scopus.com/inward/record.url?scp=70450237379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450237379&partnerID=8YFLogxK

M3 - Article

VL - 75

SP - 1025

EP - 1029

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 10

ER -